Endocyte and Nihon Medi-Physics (NMP) Enter Into Exclusive License Agreement to Develop and Commercialize Companion Imaging Diagnostic Etarfolatide for Cancer in Japan
September 05, 2013 at 16:10 PM EDT
Endocyte (Nasdaq: ECYT ), a biopharmaceutical company and leader in targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, and Nihon Medi-Physics (NMP), a market leader in the development, production and distribution of radiopharmaceuticals for nuclear medicine procedures in